Log In
BCIQ
Print this Print this
 

enzastaurin (DB102) (formerly LY317615)

  Manage Alerts
Collapse Summary General Information
Company Denovo Biopharma LLC
DescriptionSynthetic protein kinase B (PKB; Akt) and protein kinase C (PKC) beta inhibitor
Molecular Target Protein kinase C (PKC) beta (PRKCB) ; Protein kinase B (AKT) (AKT1) (PKB) (PKBA)
Mechanism of ActionProtein kinase C (PKC) beta inhibitor; Protein kinase B (PKB) (AKT1) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationB cell lymphoma
Indication DetailsTreat relapsed or refractory diffuse large B cell lymphoma (DLBCL)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/15/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today